Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14755578 | 0.83 | CYP19A1 (0.61) | RAB9ANPC1KDM4ESMN1; SMN2LTA4H | |
| SCHEMBL21283211 | 0.80 | CYP19A1 (0.45) | RAB9ANPC1KDM4ESMN1; SMN2LTA4H | |
| SCHEMBL21283206 | 0.80 | RAB9A (0.63) | RAB9ANPC1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL14755554 | 0.79 | CCR4 (0.48) | RAB9ANPC1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL5239246 | 0.79 | KDM4E (0.59) | RAB9ANPC1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL2615402 | 0.79 | GAA (0.65) | RAB9ANPC1KDM4ESREBF2SMN1; SMN2 | |
| SCHEMBL956221 | 0.79 | ALDH1A1 (0.61) | RAB9ANPC1KDM4ESREBF2SMN1; SMN2 | |
| SCHEMBL28522859 | 0.78 | RAB9A (0.73) | RAB9ANPC1KDM4ESREBF2SMN1; SMN2 | |
| SCHEMBL9454811 | 0.78 | ATP4A (0.56) | RAB9ANPC1SMN1; SMN2LTA4HMAPT | |
| SCHEMBL231094 | 0.78 | LTA4H (0.80) | RAB9ANPC1KDM4ESREBF2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
| US-7282512-B2 | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1465862-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003062192-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054819-A1 | Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors | CTSK, CTSS, CTSE | RAB9A 1828/4885NPC1 504/4885KDM4E 466/4885 |
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | RAB9A 1828/4885NPC1 504/4885KDM4E 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.